Solid Biosciences Inc. reported $0 of revenue over the trailing twelve months. 6 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $0 (to Q4 2020). Net income: −$207M, trailing twelve months to Q2 2026. Free cash flow: −$188M, trailing twelve months to Q2 2026. EPS: −$1.91, trailing twelve months to Q2 2026.

SLDBSolid Biosciences Inc.

Healthcare

$6.82+23% 1Y

$6.82

$3.9352 weeks$11.15

SLDB as reported

Solid Biosciences Inc. reported $0 of revenue over the trailing twelve months. 6 reported series are charted on this page, each one as filed.

Revenue, trailing twelve months · to Q4 2020 · every figure below is as filed, with no scoring applied

Net income: −$207M
Net income · +34% year on year · trailing twelve months to Q2 2026
Free cash flow: −$188M
Free cash flow · +52% year on year · trailing twelve months to Q2 2026
EPS: −$1.91
EPS · −32% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for SLDB, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$0	n/a	Q4 2020 · 22 quarters behind
Net income	−$207M	+34%	Q2 2026
EPS	−$1.91	−32%	Q2 2026
ROE	−70%	n/a	Q2 2026
ROA	−58%	n/a	Q2 2026
Free cash flow	−$188M	+52%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.